Experience with methotrexate in a patient with calcium pyrophosphate crystal deposition disease

The paper discusses the results of using methotrexate (MTX) in real clinical practice in a patient with calcium pyrophosphate crystal deposition resistant to traditional anti-inflammatory drugs (colchicine, nonsteroidal anti-inflammatory drugs, and hydroxychloroquine) It demonstrates the efficiency and possibility of safely using MTX at a dose of 20 mg/week during a year.